WHO recommends removing this flu variant from quadrivalent flu vaccines; researchers working on how to do it
16 minutes ago
Image: Ed Us/Unsplash/replica
because or SARS-CoV-2 At the time of Breaking into the Global Dinner, there had been no confirmed detection of Yamagata Influenza B, the influenza virus. This is one of four variants to which current vaccines provide immunity.
Asim, since March 2020, B Yamagata is missing. So other strains and flu strains will come back and voltam in their seasonal cycles.
Just like that, last week WHO The (World Health Organization) recommends that health agencies around the world exclude this ingredient from influenza vaccines.
That’s why continued manipulation of this flu variant in the lab could lead to new spread of the strain.
Challenges in updating influenza virus vaccines
Generally speaking, influenza vaccines are available in trivalent and quadrivalent varieties, with the latter being quadrivalent. tension The problem already exists. It may seem simple to just exclude vaccines and switch to trivalent immunizers, but it is actually not the same.
Generally speaking, quadrivalent manufacturers only have a license to manufacture such pods. In this way, they must go through the regulatory process to produce trivalent immunizers.
However, experts believe the timing is inappropriate. Influenza vaccine for the 2023-2024 vaccination season in the Northern Hemisphere is no longer available. The same immunization schedule for the Southern Hemisphere vaccination period is already underway. Therefore, it is too late to reformulate.
Finally, concerns remain about changes to flu vaccine content. Here, the quadrivalent vaccine consists of two type A strains and two type B strains.
In this way, the scientists studied it best to maintain the tetravalency. There are three ways to do this: use three type A viruses and one type B virus; use 3 strains and increase the dose of all; or use three viruses but increase the dose of the most dominant strain in circulation.
However, there is virtually no information to guide consultants on the best way to rediscover gaps or disparities. flu virus. More experts say there’s room for good deeds.
The FDA (Food and Drug Administration), the US equivalent of Anvisa, approved the reformulation this week. Now, other regulators and manufacturers need to communicate to understand how we do this.
